Anders Kronborg

G3 Good Governance Holdings Ltd. provides strategic advisory services. The private company is based in London, UK.

Part of LEO Fondet, LEO Laboratories Ltd. is a British dermatology company that aims to improve the lives of people living with a dermatological condition. The company is based in Hurley, UK. LEO Laboratories supplies treatments to people with medical needs in more than 130 countries around the world and strives to positively impact the lives of 125 million people through medical dermatology by 2025. Founded in 1960 and headquartered in Denmark, the company currently employs 6,000 professionals across 60 countries.

FB Dermatology Ltd. is a med-tech company, which focuses on developing and exploring patented bio-photonic technology using fluorescent light energy to stimulate the skin’s own biological processes and repair mechanisms. Its products include Kleresca acne treatment, Kleresca skin rejuvenation, Kleresca rosacea treatment, and Kleresca pre-post Treasureratment. The company is headquartered in Dublin, Ireland.

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors.